Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255242 · ClinicalTrials.gov registry record · Phase 1
Effect of Simvastatin on CF Airway Inflammation
A Phase 1 study, sponsored by Akron Children's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00255242 is a Phase 1 study that has completed, run by Akron Children's Hospital. The registered enrollment target is 40 participants.
The verdict
NCT00255242, a Phase 1 study, has completed, sponsored by Akron Children's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Individuals with cystic fibrosis (CF) have persistent infection in the airways, which the body attempts to fight by recruiting immune cells (neutrophils) to the lung. The immune system and neutrophils are unable to completely kill the bacteria, and the response to the infection leads to inflammation (swelling) of the airways and lung damage. Nitric oxide (NO) has anti-bacterial and anti-inflammatory properties in the lung. NO production is decreased in CF patients, and may contribute to the persistent infection and inflammation. Increasing the production of NO in the airways of CF patients may help decrease this inflammation and infection. Rho GTPases are molecules in the cells that line the airways that decrease the protein that makes nitric oxide (NOS). Rho proteins also increase inflammation in these cells. Rho proteins are increased in CF cells, and may partially explain the low NO and high inflammation seen in CF. Blocking the Rho protein in CF cells increases NOS, which can then produce more NO. The Rho protein can be inhibited with a drug, simvastatin (Zocor®). Simvastatin is used by millions of people to lower their cholesterol, is very safe, has few side-effects and is approved for use in children greater than 10 years of age. We propose that treating CF patients with simvastatin will increase NO produced (exhaled NO), and may decrease airway inflammation. If simvastatin has these expected effects in CF, it would be another drug that has potential to become a new therapy to fight the debilitating lung damage of the disease.
Interventions
- DRUG Simvastatin treatment for 28 days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-07 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00255242
The ClinicalTrials.gov registry entry for NCT00255242 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akron Children's Hospital, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Simvastatin treatment for 28 days is the first listed.
NCT00255242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00255242 about?
NCT00255242 is a clinical study titled "Effect of Simvastatin on CF Airway Inflammation". Individuals with cystic fibrosis (CF) have persistent infection in the airways, which the body attempts to fight by recruiting immune cells (neutrophils) to the lung. The immune system and neutrophils are unable to completely kill the bacteria, and the response to the infection leads to inflammation...
What is the current status of trial NCT00255242?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2004-07. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00255242?
The interventions under investigation include: Simvastatin treatment for 28 days (DRUG).
Who is sponsoring clinical trial NCT00255242?
This trial is sponsored by Akron Children's Hospital, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.